Astellas Pharma, Inc. - Company & Market Research Reports

Astellas formed in 2005 through the merger of Yamanouchi and Fujisawa. The company employs over 400 people in Ireland across three locations. It has successfully launched innovative products and established itself as a category leader in the therapeutic areas of Transplantation and Urology. Astellas Pharma is one of the world’s top 20 pharmaceutical companies, employing 15,000 people globally. Its headquartered at the Citywest Business Campus in Dublin 24.

REFINE BY

1,136 Results (Page 11 of 57)
- Relevance
  Sort by

Hepatocellular Carcinoma Drugs Market Report 2025

 Report
September 2025
250 Pages
Global

From

Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of Administration, Scale of Operation and Geographical Regions

 Report
August 2025
470 Pages
Global

From

Synthetic Biology: Protein Design and Engineering Market by Type of Protein Engineering Approach Used, Type of Protein, Type of Application, Type of End User and Key Geographies: Industry Trends and Global Forecasts, 2022-2035

 Report
January 2022
242 Pages
Global

From

Elastomeric Closure Components Market For Vials, Cartridges and Syringes, 2019-2030: Focus on Caps, Needle Shields, Plungers, Stoppers, Seals, Tip Caps and Other Closures

 Report
May 2019
385 Pages
Global

From

Benign Prostatic Hyperplasia Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

 Report
October 2024
97 Pages
Global

From

$Hormone Refractory Prostate Cancer Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image$